Romundstad Solfrid, Holmen Jostein, Kvenild Kurt, Hallan Hans, Ellekjaer Hanne
HUNT Research Center, Department of Public Health and General Practice, Norwegian University of Science and Technology, Verdal, Norway.
Am J Kidney Dis. 2003 Sep;42(3):466-73. doi: 10.1016/s0272-6386(03)00742-x.
To date, there are few large follow-up studies of apparently healthy subjects with microalbuminuria (MA). The aim of this study is to examine the association between MA and all-cause mortality in nondiabetic nonhypertensive individuals.
We conducted a 4.4-year mortality follow-up of 2,089 men and women (> or =20 years) without diabetes and treated hypertension, randomly selected from the population-based Nord-Trøndelag Health Study (1995 to 1997; n = 65,258). Main outcome measures were adjusted relative risk (RR) for all-cause mortality according to increasing albuminuria, defined at different albumin-creatinine ratio (ACR) levels and in 1/2 or 3 urine samples. The main analysis was performed after exclusion of those with cardiovascular disease.
There was a positive association between all-cause mortality and MA. The lowest ACR level associated with increased RR for mortality was the 60th percentile (> or =6.7 microg/mg [0.76 mg/mmol]; RR, 2.4; 95% confidence interval, 1.1 to 5.2), applying 3 urine samples with an ACR greater than the cutoff level. We found a positive association between mortality and increasing numbers of urine samples with an ACR greater than different cutoff levels, in which 3 urine samples were superior. Results persisted after adjusting for several confounders and excluding individuals with untreated hypertension (systolic blood pressure > or = 140 mm Hg/diastolic blood pressure > or = 90 mm Hg) and those who died during the first year of follow-up.
Although this study confirms the association of all-cause mortality and ACR level in apparently healthy individuals, intervention trials are necessary before clinical cutoff levels of ACR are established and before screening programs are recommended.
迄今为止,针对微量白蛋白尿(MA)的明显健康受试者的大型随访研究较少。本研究旨在探讨非糖尿病非高血压个体中MA与全因死亡率之间的关联。
我们对从基于人群的北特伦德拉格健康研究(1995年至1997年;n = 65258)中随机选取的2089名年龄≥20岁、无糖尿病且未接受高血压治疗的男性和女性进行了4.4年的死亡率随访。主要结局指标是根据不同白蛋白肌酐比值(ACR)水平以及1/2或3份尿液样本中定义的蛋白尿增加情况调整后的全因死亡率相对风险(RR)。主要分析在排除心血管疾病患者后进行。
全因死亡率与MA之间存在正相关。应用3份ACR大于临界值水平的尿液样本时,与死亡率RR增加相关的最低ACR水平为第60百分位数(≥6.7微克/毫克[0.76毫克/毫摩尔];RR,2.4;95%置信区间,1.1至5.2)。我们发现死亡率与ACR大于不同临界值水平的尿液样本数量增加之间存在正相关,其中3份尿液样本的相关性更佳。在调整了多个混杂因素并排除未治疗高血压患者(收缩压≥140毫米汞柱/舒张压≥90毫米汞柱)以及随访第一年死亡的个体后,结果依然成立。
尽管本研究证实了明显健康个体中全因死亡率与ACR水平之间的关联,但在确定ACR的临床临界值水平以及推荐筛查项目之前,仍需要进行干预试验。